Business news

    Radiopharm Theranostics (ASX:RAD) shows positive results in advanced prostate cancer study

    Article Image

    Radiopharm Theranostics reported positive outcomes from a pilot study comparing terbium-161 and lutetium-177 for metastatic castration-resistant prostate cancer.

    The study highlights Tb-161's therapeutic index, making it a candidate for advanced cancer treatment due to its unique radiation characteristics.

    Radiopharm aims to develop Tb-161 radiotherapeutics targeting prostate cancer and osteosarcoma.

    The partnership with TerThera provides exclusive access to Tb-161.

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa